SeekingAlpha · Sep 4, 2026
LENZ Therapeutics: Still Speculative But Priced For Disasters
LENZ Therapeutics: Strong Buy with $21.3 fair value (~266% upside). Vizz peak sales modeled at $375M amid risks & competition.
LE
NASDAQ · LENZ
LENZ Therapeutics, Inc.
Healthcare · Biotechnology
$3.92
Up+$0.20 (+5.24%)
Updated Sep 28, 2026, 4:43 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 684.09M
- P/E ratio
- -13.13
- Dividend yield
- 0.00%
- 52-week range
- $3.60 – $50.40
- Volume
- 923.82K
- Avg. volume
- 997.98K
Price performance
LENZ price history
1M range · 19 trading sessions · Daily adjusted prices
LENZ closed at $3.92 after 19 trading sessions, down 24.86% for the selected period.
- Last close
- $3.92
- Period change
- -24.86%
- Period low
- $3.72
- Period high
- $5.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $3.75 | $4.00 | $3.66 | $3.915 | 923.82K |
| Sep 24, 2026 | $3.75 | $3.75 | $3.595 | $3.72 | 1.01M |
| Sep 23, 2026 | $4.14 | $4.14 | $3.735 | $3.76 | 765.64K |
| Sep 22, 2026 | $4.10 | $4.175 | $4.07 | $4.13 | 511.02K |
| Sep 21, 2026 | $4.12 | $4.125 | $4.00 | $4.08 | 776.67K |
| Sep 18, 2026 | $4.10 | $4.14 | $4.04 | $4.07 | 735.16K |
| Sep 17, 2026 | $4.23 | $4.2775 | $4.01 | $4.13 | 889.18K |
| Sep 16, 2026 | $4.23 | $4.285 | $4.12 | $4.14 | 762.57K |
| Sep 15, 2026 | $4.44 | $4.44 | $4.205 | $4.23 | 819.74K |
| Sep 14, 2026 | $4.53 | $4.60 | $4.42 | $4.47 | 744.34K |
| Sep 11, 2026 | $4.71 | $4.77 | $4.50 | $4.52 | 978.25K |
| Sep 10, 2026 | $4.85 | $4.88 | $4.68 | $4.72 | 569.05K |
| Sep 9, 2026 | $5.31 | $5.405 | $4.885 | $4.91 | 705.8K |
| Sep 8, 2026 | $5.95 | $5.95 | $5.32 | $5.33 | 642.87K |
| Sep 4, 2026 | $5.75 | $5.98 | $5.615 | $5.96 | 488.96K |
| Sep 3, 2026 | $5.90 | $5.97 | $5.65 | $5.83 | 835.14K |
| Sep 2, 2026 | $5.21 | $5.81 | $5.21 | $5.80 | 993.29K |
| Sep 1, 2026 | $5.17 | $5.305 | $5.00 | $5.23 | 605.58K |
| Aug 31, 2026 | $5.06 | $5.275 | $5.008 | $5.21 | 713.74K |
Latest LENZ news
The latest Smart Investors Daily articles mentioning LENZ.
Stock researchCompany · Overview
LENZ research
Overview
Company profile and research snapshot.
Company profile
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $61.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Piper Sandler | Neutral | — |
| Jul 7, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Citigroup | Buy | — |
| May 12, 2026 | HC Wainwright & Co. | Buy | — |
| May 12, 2026 | Piper Sandler | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $12 to $7.
SeekingAlpha · Aug 12, 2026
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call August 11, 2026 4:30 PM EDTCompany ParticipantsDaniel Chevallard - Chief Financial OfficerEvert...
Benzinga · Aug 11, 2026
LENZ Therapeutics Q2 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.486M Beat $2.373M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.06) by 3.77 percent. This is a 92.45 percent decrease over losses of $(0.53) per share from
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
